{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T09:52:38Z","timestamp":1722937958326},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10067-018-4142-y","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T15:15:29Z","timestamp":1526656529000},"page":"3373-3380","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study"],"prefix":"10.1007","volume":"37","author":[{"given":"Yusa","family":"Asari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshioki","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro J.","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimito","family":"Kawahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"4142_CR1","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62:D34\u2013D41","journal-title":"J Am Coll Cardiol"},{"key":"4142_CR2","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/rheumatology\/kes140","volume":"51","author":"Y Shirai","year":"2012","unstructured":"Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M (2012) Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-center cohort. Rheumatology (Oxford) 51:1846\u20131854","journal-title":"Rheumatology (Oxford)"},{"key":"4142_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","volume":"167","author":"KP Kuhn","year":"2003","unstructured":"Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM (2003) Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167:580\u2013586","journal-title":"Am J Respir Crit Care Med"},{"key":"4142_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","volume":"179","author":"R Condliffe","year":"2009","unstructured":"Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F, Das C, Elliot CA, Johnson M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins D, Hughes RJ, Pepke-Zaba J, Coghlan JG (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179:151\u2013157","journal-title":"Am J Respir Crit Care Med"},{"key":"4142_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13075-015-0649-7","volume":"17","author":"G Kovacs","year":"2015","unstructured":"Kovacs G, Olschewski H (2015) Borderline pulmonary pressures in scleroderma\u2014a \u201cpre-pulmonary arterial hypertension\u201d condition? Arthritis Res Ther 17:123","journal-title":"Arthritis Res Ther"},{"key":"4142_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/art.37838","volume":"65","author":"CJ Valerio","year":"2013","unstructured":"Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG (2013) Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 65:1074\u20131084","journal-title":"Arthritis Rheum"},{"key":"4142_CR7","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1378\/chest.14-0194","volume":"146","author":"G Kovacs","year":"2014","unstructured":"Kovacs G, Avian A, Tscherner M, Foris V, Bachmaier G, Olschewski A, Olschewski H (2014) Characterization of patients with borderline pulmonary arterial pressure. Chest 146:1486\u20131493","journal-title":"Chest"},{"key":"4142_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jjcc.2013.04.007","volume":"62","author":"K Suzuki","year":"2013","unstructured":"Suzuki K, Akashi YJ, Manabe M, Mizukoshi K, Kamijima R, Kou S, Takai M, Izumo M, Kida K, Yoneyama K, Omiya K, Yamasaki Y, Yamada H, Nobuoka S, Miyake F (2013) Simple exercise echocardiography using a Master\u2019s two-step test for early detection of pulmonary arterial hypertension. J Cardiol 62:176\u2013182","journal-title":"J Cardiol"},{"key":"4142_CR9","doi-asserted-by":"crossref","unstructured":"Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581\u2013590","DOI":"10.1002\/art.1780230510"},{"key":"4142_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"4142_CR11","first-page":"41","volume-title":"Mixed connective tissue disease and antinuclear antibodies","author":"R Kasukawa","year":"1987","unstructured":"Kasukawa R, Tojo T, Miyawaki S (1987) Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and antinuclear antibodies. Elsevier, Amsterdam, pp 41\u201347"},{"key":"4142_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344\u2013347","journal-title":"N Engl J Med"},{"key":"4142_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/0002-8703(68)90042-2","volume":"75","author":"AM Master","year":"1968","unstructured":"Master AM (1968) The Master two-step test. Am Heart J 75:809\u2013837","journal-title":"Am Heart J"},{"key":"4142_CR14","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/eurheartj\/ehr160","volume":"32","author":"EM Lau","year":"2011","unstructured":"Lau EM, Manes A, Celermajer DS, Galie N (2011) Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J 32:2489\u20132498","journal-title":"Eur Heart J"},{"key":"4142_CR15","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/art.33460","volume":"64","author":"G Kovacs","year":"2012","unstructured":"Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Scheidl S, Tr\u00f6ster N, Hesse C, Rubin L, Olschewski H (2012) Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 64:1257\u20131262","journal-title":"Arthritis Rheum"},{"key":"4142_CR16","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3899\/jrheum.100245","volume":"37","author":"J Avouac","year":"2010","unstructured":"Avouac J, Airo P, Meune C et al (2010) Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 37:2290\u20132298","journal-title":"J Rheumatol"},{"key":"4142_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1183\/09031936.00091212","volume":"42","author":"BD Fox","year":"2013","unstructured":"Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, Eisenberg MJ, Joyal D, Hudson M, Boutet K, Serban A, Masetto A, Baron M (2013) High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 42:1083\u20131091","journal-title":"Eur Respir J"},{"key":"4142_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3109\/14397595.2015.1005871","volume":"25","author":"K Tsuchida","year":"2015","unstructured":"Tsuchida K, Yamada H, Yamasaki Y, Suzuki K, Kongoji K, Akashi Y, Ozaki S (2015) Left heart abnormalities in connective tissue disease patients with pre-capillary pulmonary hypertension as well as borderline mean pulmonary arterial pressure. Mod Rheumatol 25:744\u2013747","journal-title":"Mod Rheumatol"},{"key":"4142_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","volume":"364","author":"I Anand","year":"2004","unstructured":"Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, L\u00fcscher TF (2004) Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin a receptor antagonist trial in heart failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364:347\u2013354","journal-title":"Lancet"},{"key":"4142_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","volume":"134","author":"RM Califf","year":"1997","unstructured":"Califf RM, Adams KF, McKenna WJ et al (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST). Am Heart J 134:44\u201354","journal-title":"Am Heart J"},{"key":"4142_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/art.24267","volume":"60","author":"SC Mathai","year":"2009","unstructured":"Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569\u2013577","journal-title":"Arthritis Rheum"},{"key":"4142_CR22","first-page":"2347","volume":"33","author":"SR Johnson","year":"2006","unstructured":"Johnson SR, Patsios D, Hwang DM, Granton JT (2006) Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension. J Rheumatol 33:2347\u20132350","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4142-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4142-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T21:54:18Z","timestamp":1558130058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4142-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4142"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4142-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"assertion":[{"value":"20 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yamasaki Y and Hidehiro Y have received speaking fees from Actelion pharmaceuticals Japan Co., Ltd., Nihon Shinyaku Co., Ltd., Pfizer Japan Inc., GlaxoSmithKline K.K., and Bayer Yakuhin, Ltd. The other authors have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol conformed to the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board of the St. Marianna University School of Medicine (No. 3172).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}